Novo Breaks $598M Heartseed Pact Amid ‘Decisive Restructuring’ by New CEO

Novo Nordisk and Heartseed first partnered in 2021 to develop an investigational cell therapy for heart failure.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top